We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.02B
AUM Growth
+$60.4M
Cap. Flow
-$61.1M
Cap. Flow %
-5.98%
Top 10 Hldgs %
49.68%
Holding
183
New
37
Increased
35
Reduced
45
Closed
53

Top Buys

Rank Stock Value
1
BCOM
B Communications Ltd
BCOM
+$95.7M
2
BIIB icon
Biogen
BIIB
+$20.4M
3
CELG
Celgene Corp
CELG
+$10.3M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$7.22M
5
ATXS
Astria Therapeutics
ATXS
+$5.62M

Top Sells

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$18.8M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$12.5M
4
AMGN icon
Amgen
AMGN
+$9.61M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$6.98M

Sector Composition

Rank Sector Weight
1 Healthcare 50.75%
2 Technology 3.95%
3 Utilities 1.35%
4 Industrials 0.96%
5 Consumer Discretionary 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$20.1B
$201M 19.67%
14,615
+6,315
+76% +$584K
AGN
2
DELISTED
Allergan plc
AGN
$53.7M 5.26%
177,100
-15,000
-8% -$4.47M
XNTK icon
3
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$50.4M 4.94%
4,000
+1,000
+33% +$51.8K
TEVA icon
4
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$38.4M 3.76%
6,500
+3,000
+86% +$185K
GILD icon
5
Gilead Sciences
GILD
$162B
$37.5M 3.67%
320,000
– –
PFE icon
6
Pfizer
PFE
$143B
$29.3M 2.87%
921,210
-158,100
-15% -$5.15M
ABBV icon
7
AbbVie
ABBV
$443B
$27.3M 2.68%
407,000
– –
BIIB icon
8
Biogen
BIIB
$30B
$24.5M 2.4%
60,730
+50,730
+507% +$20.4M
MRK icon
9
Merck
MRK
$322B
$22.8M 2.23%
419,200
+26,200
+7% +$1.47M
XLV icon
10
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$22.3M 2.19%
3,000
+1,700
+131% +$126K
CELG
11
DELISTED
Celgene Corp
CELG
$18.5M 1.81%
160,000
+90,000
+129% +$10.3M
PRGO icon
12
CALL
Perrigo
PRGO
$1.4B
$18.5M 1.81%
+1,000
New +$191K
BMRN icon
13
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
$13.7M 1.34%
+1,000
New +$124K
VTRS icon
14
Viatris
VTRS
$20.4B
$11.9M 1.16%
175,000
-97,100
-36% -$6.86M
ORA icon
15
Ormat Technologies
ORA
$6B
$11.3M 1.11%
80,092
– –
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
$10.5M 1.03%
120,000
+7,545
+7% +$646K
TEVA icon
17
Teva Pharmaceuticals
TEVA
$40.8B
$10.5M 1.03%
177,300
-225,519
-56% -$13.9M
BHC icon
18
Bausch Health
BHC
$2.57B
$10.2M 1%
45,750
– –
NVS icon
19
Novartis
NVS
$297B
$9.83M 0.96%
111,600
– –
AMGN icon
20
Amgen
AMGN
$208B
$9.24M 0.91%
60,200
-60,000
-50% -$9.61M
CXRX
21
DELISTED
Concordia International Corp. Common Stock
CXRX
$9.03M 0.88%
+100,000
New +$7.22M
VRNT
22
DELISTED
Verint Systems
VRNT
$8.47M 0.83%
273,709
+33,626
+14% +$1.09M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.6B
$8.21M 0.8%
60,000
-20,000
-25% -$2.48M
CHKP icon
24
Check Point Software Technologies
CHKP
$13B
$7.25M 0.71%
91,087
+19,160
+27% +$1.62M
SHPG
25
DELISTED
Shire pic
SHPG
$6.87M 0.67%
134,751
– –
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sphera Funds Management held 183 positions worth $1.02B, up 6.3% from $961M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management withdrew a net $61.1M in Q2 2015, closing 53 positions and reducing 45 holdings. Its most notable exit was Endo International plc, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 54% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in B Communications Ltd worth $6.45M.

  • Sphera Funds Management's largest Q2 2015 buy was B Communications Ltd: 5,977,000 shares worth $6.45M.
  • Sphera Funds Management added most to Biogen in Q2 2015, an estimated $20.4M increase.
  • Sphera Funds Management's biggest Q2 2015 reduction was Teva Pharmaceuticals, cutting an estimated $13.9M.
  • Sphera Funds Management fully exited Endo International plc in Q2 2015, selling an estimated $18.8M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.02B portfolio in Q2 2015.
  • Sphera Funds Management opened 37 new positions and closed 53 in Q2 2015.
  • Sphera Funds Management's portfolio value rose 6.3% quarter-over-quarter to $1.02B.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.